NASDAQ:MNPR Monopar Therapeutics (MNPR) Stock Price, News & Analysis $80.76 +0.77 (+0.96%) As of 01:44 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Monopar Therapeutics Stock (NASDAQ:MNPR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Monopar Therapeutics alerts:Sign Up Key Stats Today's Range$79.33▼$82.3550-Day Range$80.00▼$123.8452-Week Range$50.07▼$124.82Volume171,879 shsAverage Volume211,853 shsMarket Capitalization$542.09 millionP/E RatioN/ADividend YieldN/APrice Target$121.36Consensus RatingModerate Buy Company Overview Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for cancer. The company’s programs are designed to address significant limitations associated with existing cancer therapies, including treatment resistance and dose-limiting toxicity. Monopar’s lead clinical program is camsirubicin, an investigational next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The drug is designed to retain the anticancer activity of anthracyclines while reducing the risk of cumulative heart damage associated with conventional doxorubicin. Monopar is also developing MNPR-101, a urokinase plasminogen activator receptor-targeting platform intended for use in radiopharmaceutical imaging and therapy for aggressive cancers. Founded in 2014 and headquartered in Wilmette, Illinois, Monopar became a publicly traded company in 2019. Its activities have primarily centered on research, clinical development and collaborations rather than commercial product sales. The company is led by Chief Executive Officer Chandler Robinson and serves the oncology market through drug-development programs conducted primarily in the United States.AI Generated. May Contain Errors. Read More Monopar Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreMNPR MarketRank™: Monopar Therapeutics scored higher than 58% of companies evaluated by MarketBeat, and ranked 397th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingMonopar Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 2 strong buy ratings, 7 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialMonopar Therapeutics has a consensus price target of $121.36, representing about 48.8% upside from its current price of $81.57.Amount of Analyst CoverageMonopar Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Monopar Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Monopar Therapeutics are expected to decrease in the coming year, from ($2.98) to ($4.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Monopar Therapeutics is -37.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Monopar Therapeutics is -37.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMonopar Therapeutics has a P/B Ratio of 3.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Monopar Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.93% of the float of Monopar Therapeutics has been sold short.Short Interest Ratio / Days to CoverMonopar Therapeutics has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Monopar Therapeutics has recently decreased by 0.96%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMonopar Therapeutics does not currently pay a dividend.Dividend GrowthMonopar Therapeutics does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.51 News SentimentMonopar Therapeutics has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Monopar Therapeutics this week, compared to 3 articles on an average week.Search Interest2 people have searched for MNPR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Monopar Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,363,694.00 in company stock.Percentage Held by Insiders9.70% of the stock of Monopar Therapeutics is held by insiders.Percentage Held by Institutions1.83% of the stock of Monopar Therapeutics is held by institutions.Read more about Monopar Therapeutics' insider trading history. Receive MNPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Monopar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MNPR Stock News HeadlinesPiper Sandler Sticks to Their Buy Rating for Monopar Therapeutics Inc (MNPR)September 29 at 2:39 PM | theglobeandmail.comMonopar Therapeutics (NASDAQ:MNPR) CEO Chandler Robinson Sells 29,056 Shares of Company StockSeptember 29 at 4:07 AM | insidertrades.comMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation.September 30 at 1:00 AM | Paradigm Press (Ad)Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026August 19, 2026 | markets.businessinsider.comMonopar Appoints Jeffrey D. Kent, M.D.August 19, 2026 | globenewswire.comMonopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For 'Strong Buy'August 18, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR), Achieve Life Sciences (ACHV) and OptimizeRx (OPRX)August 15, 2026 | theglobeandmail.comMonopar cut to neutral at Cantor on valuationAugust 13, 2026 | msn.comSee More Headlines MNPR Stock Analysis - Frequently Asked Questions How have MNPR shares performed this year? Monopar Therapeutics' stock was trading at $65.30 at the beginning of 2026. Since then, MNPR shares have increased by 24.9% and is now trading at $81.5660. How were Monopar Therapeutics' earnings last quarter? Monopar Therapeutics Inc. (NASDAQ:MNPR) posted its quarterly earnings data on Wednesday, August, 12th. The company reported ($0.62) earnings per share for the quarter, beating analysts' consensus estimates of ($0.64) by $0.02. When did Monopar Therapeutics' stock split? Monopar Therapeutics shares reverse split on the morning of Tuesday, August 13th 2024.The 1-5 reverse split was announced on Friday, August 9th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. Does Monopar Therapeutics have any subsidiaries? Monopar Therapeutics subsidiaries include Monopar Therapeutics Pty Ltd, and Monopar Therapeutics SARL. When did Monopar Therapeutics IPO? Monopar Therapeutics (MNPR) raised $9 million in an initial public offering (IPO) on Thursday, December 19th 2019. The company issued 1,100,000 shares at $8.00 per share. JonesTrading served as the underwriter for the IPO and Arcadia Securities was co-manager. How do I buy shares of Monopar Therapeutics? Shares of MNPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Monopar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Monopar Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Avino Silver & Gold Mines (ASM), GlycoMimetics (GLYC), Gold.com (GOLD), Tonix Pharmaceuticals (TNXP) and Viking Therapeutics (VKTX). Company Calendar Last Earnings8/12/2026Today9/30/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (22m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 MNPR's financial health is in the Green zone, according to TradeSmith. MNPR has been in this zone for over 22 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MNPR CIK1645469 Webwww.monopartx.com Phone847-388-0349FaxN/AEmployees22Year Founded2014Price Target and Rating Average Price Target for Monopar Therapeutics$121.36 High Price Target$145.00 Low Price Target$100.00 Potential Upside/Downside+50.8%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.72 million Net MarginsN/A Pretax MarginN/A Return on Equity-13.08% Return on Assets-12.79% Debt Debt-to-Equity RatioN/A Current Ratio33.56 Quick Ratio33.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$20.62 per share Price / Book3.90Miscellaneous Outstanding Shares6,712,000Free Float6,061,000Market Cap$540.22 million OptionableNot Optionable Beta1.49 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:MNPR) was last updated on 9/30/2026 by MarketBeat.com Staff. From Our PartnersSMX: From Under-the-Radar to Must-Watch!SMX (Security Matters) PLC embeds molecular-level markers into plastics, metals, fuels, and textiles, giving e...Equiscreen | SponsoredLegendary U.S. Congressman Issues WarningDr. Ron Paul warns a dangerous experiment is already underway in Washington, involving at least 27 billion dol...Altimetry | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altuche...Paradigm Press | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
